US Bancorp

US Bancorp’s Arcutis Biotherapeutics ARQT Stock Holding History

US Bancorp’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.35K	Sell	142 -119	-46%	-$3.04K	﹤0.01%	3683
2025 Q4	$7.58K	Buy	+261	New	+$6.68K	﹤0.01%	3419
2025 Q3	–	Sell	-62	Closed	-$869	–	4016
2025 Q2	$869	Sell	62 -57	-48%	-$799	﹤0.01%	3965
2025 Q1	$1.86K	Buy	119 +95	+396%	+$1.34K	﹤0.01%	3898
2024 Q4	$334	Buy	+24	New	+$263	﹤0.01%	4051
2023 Q3	–	Sell	-80	Closed	-$762	–	3988
2023 Q2	$762	Buy	+80	New	+$888	﹤0.01%	3835
2023 Q1	–	Sell	-480	Closed	-$7.1K	–	4084
2022 Q4	$7.1K	Buy	480 +428	+823%	+$7.48K	﹤0.01%	3401
2022 Q3	$1K	Sell	52 -233	-82%	-$5.28K	﹤0.01%	3914
2022 Q2	$6K	Hold	285	–	–	﹤0.01%	3503
2022 Q1	$5K	Buy	+285	New	+$4.82K	﹤0.01%	3588
2021 Q4	–	Sell	-114	Closed	-$3K	–	4087
2021 Q3	$3K	Buy	114 +22	+24%	+$502	﹤0.01%	3759
2021 Q2	$3K	Buy	+92	New	+$2.59K	﹤0.01%	3708

Other funds holding ARQT

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return